Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, January 9, 2010

Updated News from the National MS Society, how work is proceeding on the pursuit of the CCSVI lead

UPDATE: Research into Blood Flow in the Brain and Venous Insufficiency, or CCSVI, in MS – Letters of Intent Received from Request for Research Applications Released Worldwide



...............................................................................

If not Yet receiving the "Stu's Views and MS News" weekly MS related e-Newseltter. Take 20 seconds to register. Visit: http://www.msviewsandnews.org

#################################
Si todavía no recibe "Stu's Views and MS News, el boletín de email semanal relacionado a la EM, tome 20 segundos para inscribirse. Visite http://www.msviewsandnews.org .
#################################
S'il ne reçoit pas encore les «vues Stu et MS Nouvelles" MS hebdomadaires sur e-Newseltter. Prenez 20 secondes pour s'inscrire. Visite: http://www.msviewsandnews.org.
#################################
Wenn noch nicht die "Stu's Views und MS-News" in der Woche MS zu E-Newseltter. Nutzen Sie 20 Sekunden zu registrieren.Führung: http://www.msviewsandnews.org

============================================

Medical marijuana up for final vote Monday in New Jersey

lehigh valley live.com -

By Kurt Bresswein

January 08, 2010


Coming down to the wire, both chambers of the New Jersey Legislature are scheduled to vote Monday on legalizing medical marijuana.

The Assembly on Thursday amended its bill to reflect months of negotiations over its version and that of the Senate. An Assembly committee last June tightened the Senate version approved last February, removing such provisions as allowing patients to grow marijuana at home.

Monday marks the final voting day of the 2008-09 session, before the 214th Legislature begins its work Jan. 12. A vote by the full Assembly is scheduled to be followed by a concurrence vote in the Senate, staff from the primary Assembly and Senate sponsors' offices said today.

>> READ MORE <<



..........................................................
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Adeona Announces Additional $860,000 Grant for Oral Estriol Multiple Sclerosis Clinical Tria

Number of Clinical Sites Doubled to Speed Enrollment

Adeona Pharmaceuticals, Inc., (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced today that the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, Director, UCLA Multiple Sclerosis Program, UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at sixteen sites in the US and will enroll up to 150 female Multiple Sclerosis (MS) patients. Investigators will administer Trimesta along with glatimer acetate (Copaxone®), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society's Southern California chapter, with support from the National Institutes of Health (NIH).


Continue to read by clicking here

-------------------------------------------------------------------------------

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Get an Insider’s Perspective of the National MS Society’s Latest Plans, Projects and More

Updated January 8, 2010

The following news sheets contain information regarding the operations and programs of the Society. This information ensures our staff and volunteers are engaged and informed about important ongoing work of the organization. Information contained in this file will contain links to our internal information system, which is password protected to ensure that we honor and protect the privacy of our employees as well as safeguard our systems and any proprietary information. If you would like more information regarding a topic presented, please contact your local National MS Society chapter.

News Sheets 1/08/10

News Sheets 12/18/09

News Sheets 12/11/09

News Sheets 12/04/09

News Sheets 11-20-09

New Sheets 11-13-09

News Sheets 11-06-09

News Sheets 10-30-09

News Sheets 10-23-09

News Sheets 10-16-09

News Sheets 10-09-09

News Sheets 10-02-09

News Sheets 9-25-09

News Sheets 9-18-09

News Sheet 9-11-09

News Sheet 9-4-09

News Sheet 8-28-09

News Sheet 8-14-09


^^^^^^^^^^^^^^^^^^^^^^^^^^^^


.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Friday, January 8, 2010

Teva Pharma Sees Copaxone Pressure Coming But Not from Generic

By Thomas Gryta, Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)-. (TEVA) doesn't expect generic competition for its blockbuster multiple sclerosis treatment Copaxone before 2014, but the company warned that competition from oral MS drugs will likely pressure sales before that time.

The Copaxone battle is notable because it pits the world largest generics company, which has benefited from challenging the patents of other pharmaceutical companies, against generic competitors to protect the exclusivity of its own brand.

Momenta Pharmaceuticals Inc. (MNTA) and Mylan Inc. (MYL) have both filed to produce generic versions of Copaxone, a process that is likely to span years. The drug, one of the world's best selling MS treatments with 2008 sales of $2.26 billion, is a key component of Teva's business.


+++++++++++++++++++++++++++++++++++++++++++
.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Biogen to reinstate monthly PML updates

Friday, January 08, 2010


BIOGEN IDEC – the Boston-based pharmaceutical firm which co-owns the Tysabri multiple sclerosis drug with Athlone-based Elan – is set to re-instate monthly updates of outbreaks of PML, the rare brain disease which is a potential side effect of using Tysabri, after announcing four further cases of the condition.


The four new instances of PML were developed by Tysabri users in the US during November and bring the total number of outbreaks amongst users of the treatment to 28. Biogen recently ceased updating on new PML cases on its website, but is likely to release data for December before the end of this month.


CLICK to Read more

++++++++++++++++++++++++++++++++

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Complementary & Alternative Medicine Part One - for Multiple Sclerosis


The National MS Society's
MS Learn Online Presents:


Today's new Feature Presentation:

Part one of a two-part webcast series that explores:

  • Diet
  • Supplements
  • Physical medicine
  • Other options
If you have a pop-up blocker, you will need to disable it prior to participating in a MS Learn Online webcast.


++++++++++++++++++++++++++++++++++

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you

============================================

Thursday, January 7, 2010

Biogen discloses more PML cases

Wednesday, January 6, 2010 - Boston Business Journal - by Julie M. Donnelly

Biogen Idec says that four more cases of the rare and serious neurological infection known as PML have been detected in patients taking its drug for multiple sclerosis, Tysabri.

That brings the total number of progressive multifocal leukoencephalopathy cases to 28 since July 2008.

Officials at the Cambridge, Mass.-based biotechnology company (Nasdaq: BIIB) say that even with the addition of four new cases between the end of October and the end of November, the risk of developing the infection is not higher than expected.

“The risk for patients taking the drug for less than a year is 0.4 per 1,000 and the risk for those taking it for more than two years is one in 1000, consistent with what it says on the label,” said Naomi Aoki, Biogen’s director of public affairs.

Since the risks increase the longer a patient takes the drug, the number of PML cases is expected to rise. A disproportionate share of the cases have been detected outside the U.S. Biogen officials believe a number of factors are at play in this trend, but that the relatively heavier use of other immunosuppressant treatments overseas may play a role.

Continue to read by clicking here

..................................................................


.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Wednesday, January 6, 2010

Check Out Drug Interactions Checker

Obtained from: about.com:multiple sclerosis
Written by: Julie Stachowiak, Ph.D.

I am bringing this tool to your attention again, as I think it is just so important (and the tool is so cool). Let's start out the new year by taking a look at all of the meds that we are taking and making sure that they "play nicely" together. I know I have introduced a couple of over-the-counter cold symptom remedies into my repetoire this season and had some plans to bring in some supplements. Think I'll put them all in here and see what the results say...

Read the full article: Check Out Drug Interactions Checker

--------------------------------------------------------------------------

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Can Vitamin D Help Reduce Risk of Diseases?

January 5, 2010 · Published By Editor of EVLiving.com

What if there was one pill you could take that could possibly help reduce your risk for 17 types of cancer, heart disease, multiple sclerosis, osteoporosis, and childhood asthma – and it wasn’t a prescription drug? It’s a pill that some recent studies indicate could lower the incidence of breast cancer by as much as 50 percent and reduce our national cost of cancer treatment by $25 billion annually, while costing consumers only pennies a day.

Click here to continue reading about Vitamin D's benefits

..........................................................................................

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Oral Cladribine is Still Expected to be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States

Despite FDA's Letter to Merck Serono, Oral Cladribine is Still Expected to be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States

Novartis/Mitsubishi Tanabe's FTY-720 Remains on Track for Launch in Early 2011, According to Findings from Decision Resources

WALTHAM, Mass., Jan. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

The Pharmacor finding from the topic entitled Multiple Sclerosis reveals that, although oral cladribine's first-to-market advantage over FTY-720 will be reduced as a result of a likely delay to market caused by the FDA's action, oral cladribine is still expected to launch in the U.S. in 2010 while FTY-720 remains on track to launch in early 2011. Merck Serono, which has not released details about the contents of the letter that its U.S. affiliate EMD Serono received from the FDA in late 2009, has indicated that it is in discussions with the FDA regarding the resubmission of the new drug application for oral cladribine.

"Typically, the FDA will issue an RTF letter if some aspect of a new drug application is incomplete but this action is not a reflection of the FDA's opinion regarding a drug's efficacy or safety profiles," said Decision Resources Analyst Bethany Kiernan, Ph.D. "At this time, we assume the RTF letter will not significantly delay the 2010 launch of oral cladribine in the United States."

Continue reading this article from the PRNewsWire


++++++++++++++++++++++++++++++++++

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Tuesday, January 5, 2010

Blog Links concerning CCSVI (Chronic Cerebrospinal Venous Insufficiency) in MS

Dec 31, 2009
CTEVD/CCSVI STUDY. For Study Details, click here. Review other articles onCCSVI from our website or from my blog, by using the search boxes found at each. If not yet receiving my weekly MS related e-Newsletter, visit our website to ...
Dec 20, 2009
He plans to use ultrasound and MRI scans to confirm if those with MS also have CCSVI and if their family members have the abnormalities too. Prof. Mark Haake, a neuro-imaging scientist at McMaster University and Wayne State University ...
Dec 15, 2009
Italian MS research (on CCSVI) brings hopeful patients to private Vancouver clinic. Surgical centre will do tests for $2300 to determine if they're candidates for treatment. BY PAMELA FAYERMAN, VANCOUVER SUN. DECEMBER 14, 2009 ...
Dec 18, 2009
Return to this page to leave any comments you have or visit this facebook page to leave a comment on CCSVI. What do you think? Tell us your thoughts on this potential means for MS. Posted by Stuart at 7:54 AM ...


Find more article on CCSVI posted on this blog by using our Blog Search (found upper right). Type: CCSVI, click enter, then click on the page numbers that appear under the first few links.




.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Monday, January 4, 2010

MS Related: Tai Chi has become a popular form of relaxation


It's been referred to as meditation in motion. Dating back to ancient China, tai chi is a form of martial art that has been turned into an increasingly popular form of exercise.

"After doing tai chi, all the chi in your body circulates. Your hands should turn pink and you should be sweating a little bit," Tina Wu, who leads the class at the Healthplex, said. "You concentrate while doing it, connecting your body and mind. And after, you should feel good."

A 2007 survey by the National Center for Health Statistics and the National Center for Complementary and Alternative Medicine found that more than 2.3 million adults in the U.S. had used tai chi, which is a series of slow, graceful movements that flow into each other, within the past 12 months.

Numerous studies have also shown various health benefits of tai chi, which no one knows better than Wu.

About nine years ago, Wu lost her brother, and during the grieving process, she began to have severe chronic back pain, as well as a fast heartbeat and eventually symptoms of what her doctor thought initially could be multiple sclerosis.

Click here, to read complete article

................................................................

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

A Poem from an MS Patient

Thrill Ride (by Yvonne Decelis)

It's a slow roller-coaster
every day
I feel my brain peel away
layer by layer
piece by piece
it's much smaller now than it was
fifteen years ago
everything is a little harder to do now
than it was
ten years ago
five years ago
yesterday
this morning
now...

.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Babies born in April face a "higher risk" of Multiple Sclerosis

Babies born in April face an increased risk of suffering from multiple sclerosis in later life, possibly as a result of their mothers' lack of exposure to sunlight, according to research.


Scientists found mothers who were pregnant during the autumn and winter were most likely to give birth to those who would suffer from the debilitating neurological disease.

The researchers, based at Glasgow university and the city's Southern General Hospital, believe the spike in cases among children born in the spring may be due to a shortage of vitamin D because duing a vital developmental stage their mothers are exposed to less sunshine.

Vitamin D, which is largely gained through sunlight and food, is known to regulate a gene that can predispose individuals to MS. If the gene is passed on to the unborn child, without being regulated by a sufficient amount of vitamin D, it could "hard wire" them to develop the disease in later life.

The new study, published in the European Journal of Neurology, is the biggest yet carried out in Scotland, which has the highest rate of MS in the world.

MS affects about 85,000 people in the UK and 10,500 in Scotland. While the cause is not known, experts believe a combination of genetic and environmental factors are responsible for the condition.

Continue to read from this TELEGRAPH.co.UK article


.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================